Moritz Seitzer1, Sylvia Klapper2, Humphrey D Mazigo3, Ulrike Holzgrabe2, Andreas Mueller1,4. 1. Medical Mission Institute, Würzburg, Bavaria, Germany. 2. Institute of Pharmacy and Food Chemistry, Julius-Maximilians-University of Würzburg, Würzburg, Germany. 3. Department of Medical Parasitology and Entomology, Catholic University of Health and Allied Sciences, Mwanza, Lake Zone, United Republic of Tanzania. 4. Department of Tropical Medicine, Klinikum Würzburg Mitte gGmbH (Medical Mission Hospital), Würzburg, Germany.
Abstract
BACKGROUND: Even though the international combat against Neglected Tropical Diseases such as schistosomiasis or soil-transmitted helminthiases depends on reliable therapeutics, anthelminthic pharmacovigilance has been neglected on many national African drug markets. Therefore, quality and composition of Albendazole, Mebendazole and Praziquantel locally collected in Burkina Faso, Côte d'Ivoire, Ghana and Tanzania were analysed. METHODS: Samples of 88 different batches were obtained from randomly selected facilities. Sampling took place in Northwest Tanzania, Western Burkina Faso, Southeast Côte d'Ivoire and Southwest Ghana. Visual examination of both packaging and samples was performed according to the WHO 'Be Aware' tool. Products were then screened with the GPHF Minilab, consisting of tests of mass uniformity, disintegration times and thin-layer chromatography (TLC). Confirmatory tests were performed according to international pharmacopoeiae, applying assays for dissolution profiles and high-performance liquid chromatography (HPLC). FINDINGS: Despite minor irregularities, appearance of the products did not hint at falsified medicines. However, 19.6% of the brands collected in Ghana and Tanzania were not officially licensed for sale. Mass uniformity was confirmed in 53 out of 58 brands of tablets. 41 out of 56 products passed disintegration times; 10 out of the 15 failing products did not disintegrate at all. Evaluating TLC results, only 4 out of 83 batches narrowly missed specification limits, 18 batches slightly exceeded them. Not more than 46.3% (31 / 67) of the tablets assayed passed the respective pharmaceutical criteria for dissolution. HPLC findings confirmed TLC results despite shifted specification limits: 10 out of 83 tested batches contained less than 90%, none exceeded 110%. CONCLUSION: In the four study countries, no falsified anthelminthic medicine was encountered. The active pharmaceutical ingredient was not found to either exceed or fall below specification limits. Galenic characteristics however, especially dissolution profiles, revealed great deficits.
BACKGROUND: Even though the international combat against Neglected Tropical Diseases such as schistosomiasis or soil-transmitted helminthiases depends on reliable therapeutics, anthelminthic pharmacovigilance has been neglected on many national African drug markets. Therefore, quality and composition of Albendazole, Mebendazole and Praziquantel locally collected in Burkina Faso, Côte d'Ivoire, Ghana and Tanzania were analysed. METHODS: Samples of 88 different batches were obtained from randomly selected facilities. Sampling took place in Northwest Tanzania, Western Burkina Faso, Southeast Côte d'Ivoire and Southwest Ghana. Visual examination of both packaging and samples was performed according to the WHO 'Be Aware' tool. Products were then screened with the GPHF Minilab, consisting of tests of mass uniformity, disintegration times and thin-layer chromatography (TLC). Confirmatory tests were performed according to international pharmacopoeiae, applying assays for dissolution profiles and high-performance liquid chromatography (HPLC). FINDINGS: Despite minor irregularities, appearance of the products did not hint at falsified medicines. However, 19.6% of the brands collected in Ghana and Tanzania were not officially licensed for sale. Mass uniformity was confirmed in 53 out of 58 brands of tablets. 41 out of 56 products passed disintegration times; 10 out of the 15 failing products did not disintegrate at all. Evaluating TLC results, only 4 out of 83 batches narrowly missed specification limits, 18 batches slightly exceeded them. Not more than 46.3% (31 / 67) of the tablets assayed passed the respective pharmaceutical criteria for dissolution. HPLC findings confirmed TLC results despite shifted specification limits: 10 out of 83 tested batches contained less than 90%, none exceeded 110%. CONCLUSION: In the four study countries, no falsified anthelminthic medicine was encountered. The active pharmaceutical ingredient was not found to either exceed or fall below specification limits. Galenic characteristics however, especially dissolution profiles, revealed great deficits.
Authors: Nathan C Lo; David G Addiss; Peter J Hotez; Charles H King; J Russell Stothard; Darin S Evans; Daniel G Colley; William Lin; Jean T Coulibaly; Amaya L Bustinduy; Giovanna Raso; Eran Bendavid; Isaac I Bogoch; Alan Fenwick; Lorenzo Savioli; David Molyneux; Jürg Utzinger; Jason R Andrews Journal: Lancet Infect Dis Date: 2016-11-30 Impact factor: 25.071
Authors: Jia Li; Yulan Wang; Alan Fenwick; T Andrew Clayton; Yu Y K Lau; Cristina Legido-Quigley; John C Lindon; Jürg Utzinger; Elaine Holmes Journal: J Pharm Biomed Anal Date: 2007-06-23 Impact factor: 3.935
Authors: Folahanmi T Akinsolu; Priscilla O Nemieboka; Diana W Njuguna; Makafui N Ahadji; Dora Dezso; Orsolya Varga Journal: Int J Environ Res Public Health Date: 2019-05-31 Impact factor: 3.390